1 |
Mastrorilli G, Fiorentino F, Tucci C, Lombardi G, Aghemo A, Colombo GL. Cost Analysis of Platelet Transfusion in Italy for Patients with Chronic Liver Disease and Associated Thrombocytopenia Undergoing Elective Procedures. CEOR 2022;Volume 14:205-20. [DOI: 10.2147/ceor.s354470] [Reference Citation Analysis]
|
2 |
Flisiak R, Antonov K, Drastich P, Jarcuska P, Maevskaya M, Makara M, Puljiz Ž, Štabuc B, Trifan A. Practice Guidelines of the Central European Hepatologic Collaboration (CEHC) on the Use of Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease Undergoing Invasive Procedures. J Clin Med 2021;10:5419. [PMID: 34830701 DOI: 10.3390/jcm10225419] [Reference Citation Analysis]
|
3 |
Wada N, Uojima H, Satoh T, Okina S, Iwasaki S, Shao X, Takiguchi H, Arase Y, Itokawa N, Atsukawa M, Miyazaki K, Hidaka H, Kako M, Kagawa T, Iwakiri K, Horie R, Suzuki T, Koizumi W. Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease. Dig Dis 2021;39:234-42. [PMID: 32759604 DOI: 10.1159/000510692] [Reference Citation Analysis]
|
4 |
Singh VK, Seed TM. Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure. Front Pharmacol 2021;12:624844. [PMID: 34040517 DOI: 10.3389/fphar.2021.624844] [Reference Citation Analysis]
|